4.8 Article

The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progression

Journal

MOLECULAR CELL
Volume 29, Issue 1, Pages 102-111

Publisher

CELL PRESS
DOI: 10.1016/j.molcel.2007.12.015

Keywords

-

Funding

  1. NCI NIH HHS [R01 CA098172-06, CA090465, R01 CA098172-05, R01 CA090465-06, R01 CA098172-04, R01 CA098172, R01 CA090465-06S1, R01 CA078831, R01 CA090465-05, CA098172, R01 CA090465] Funding Source: Medline
  2. NIGMS NIH HHS [R01 GM055360, T32 GM008216, GM55360] Funding Source: Medline

Ask authors/readers for more resources

Polycomb genes encode critical regulators of both normal stem cells and cancer stem cells. A gene signature that includes Polycomb genes and additional genes coregulated with Polycomb genes was recently identified. The expression of this signature has been reported to identify tumors with the cancer stem cell phenotypes of aggressive growth, metastasis, and therapy resistance. Most members of this 11 gene signature encode proteins with well-defined roles in human cancer. However, the function of the signature member USP22 remains unknown. We report that USP22 is a previously uncharacterized subunit of the human SAGA transcriptional cofactor complex. Within SAGA, USP22 deubiquitylates histone H2B. Furthermore, USP22 is recruited to specific genes by activators such as the Myc oncoprotein, where it is required for transcription. In support of a functional role within the Polycomb/cancer stem cell signature, USP22 is required for appropriate progression through the cell cycle.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available